The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Anti-IL5 therapies for asthma
Open accessAbstract
BACKGROUND: This review is the first update of a previously published review in The Cochrane Library (Issue 7, 2015). Interleukin-5 (IL-5) is the main cytokine involved in the activation of eosinophils, which cause airway inflammation and are a classic feature of asthma. Monoclonal antibodies targeting IL-5 or its receptor (IL-5R) have been developed, with recent studies suggesting that they reduce asthma exacerbations, improve health-related quality of life (HRQoL) and lung function. These are being incorporated into asthma guidelines. OBJECTIVES: To compare the effects of therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) with placebo on exacerbations, health-related qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments. SEARCH METHODS: We searched the Cochrane Airways Trials Register, clinical trials registries, manufacturers' websites, and reference lists of included studies. The most recent search was March 2017. SELECTION CRITERIA: We included randomised controlled trials comparing mepolizumab, reslizumab and benralizumab versus placebo in adults and children with asthma. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected by Cochrane. MAIN RESULTS: ) of between 0.08 L and 0.11 L.There were no excess serious adverse events with any anti-IL-5 treatment, and indeed a reduction in favour of mepolizumab that could be due to a beneficial effect on asthma-related serious adverse events. There was no difference compared to placebo in adverse events leading to discontinuation with mepolizumab or reslizumab, but significantly more discontinued benralizumab than placebo, although the absolute numbers were small (36/1599 benralizumab versus 9/998 placebo).Mepolizumab, reslizumab and benralizumab all markedly reduced blood eosinophils, but benralizumab resulted in almost complete depletion, whereas a small number remained with mepolizumab and reslizumab. The implications for efficacy and/or adverse events are unclear. AUTHORS' CONCLUSIONS: Overall our study supports the use of anti-IL-5 treatments as an adjunct to standard of care in people with severe eosinophilic asthma and poor control. These treatments roughly halve the rate of asthma exacerbations in this population. There is limited evidence for improved HRQoL scores and lung function, which may not meet clinically detectable levels. There were no safety concerns regarding mepolizumab or reslizumab, and no excess serious adverse events with benralizumab, although there remains a question over adverse events significant enough to prompt discontinuation.Further research is needed on biomarkers for assessing treatment response, optimal duration and long-term effects of treatment, risk of relapse on withdrawal, non-eosinophilic patients, children (particularly under 12 years), and comparing anti-IL-5 treatments to each other and, in people eligible for both, to anti-immunoglobulin E. For benralizumab, future studies should closely monitor rates of adverse events prompting discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
(2008) · Cited by 3,790
Development of the asthma control test
Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., Murray, J. J., & Pendergraft, T. B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.008 · Cited by 2,906
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Asthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Juniper, E. F., Guyatt, G. H., Epstein, R. S., Ferrie, P. J., Jaeschke, R., & Hiller, T. K. (1992) · Thorax · doi:10.1136/thx.47.2.76 · Cited by 1,232
Castro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., Wangoo, A., Ludwig, M. S., Barnes, N., Robinson, D., & Kay, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17974 · Cited by 841
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, G. M., O'Byrne, P. M., Boulet, L.-P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J. M., Boedigheimer, M., Davis, B. E., Dias, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402895 · Cited by 789
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Flood-Page, P., Swenson, C., Faiferman, I., Matthews, J., Williams, M., Brannick, L., Robinson, D., Wenzel, S., Busse, W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
Castro, M., Mathur, S., Hargreave, F., Boulet, L.-P., Xie, F., Young, J., Wilkins, H. J., Henkel, T., & Nair, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0396oc · Cited by 716
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants
Blanken, M. O., Rovers, M. M., Molenaar, J. M., Winkler-Seinstra, P. L., Meijer, A., Kimpen, J. L. L., & Bont, L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211917 · Cited by 671
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Chupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L., Magnan, A., & ten Brinke, A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30125-x · Cited by 599
Kolbeck, R., Kozhich, A., Koike, M., Peng, L., Andersson, C. K., Damschroder, M. M., Reed, J. L., Woods, R., Dall'Acqua, W. W., Stephens, G. L., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.004 · Cited by 586
Ortega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Hanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
Price, D., Fletcher, M., & van der Molen, T. (2014) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2014.9 · Cited by 554
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Allergen-specific immunotherapy with recombinant grass pollen allergens
Jutel, M., Jaeger, L., Suck, R., Meyer, H., Fiebig, H., & Cromwell, O. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.06.004 · Cited by 519
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Laviolette, M., Gossage, D. L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., Busse, W. W., Wenzel, S., Wu, Y., Datta, V., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.020 · Cited by 511
Kips, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F., & Pauwels, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494
Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Milavetz, G. (2008) · Journal of Pharmacy Technology · doi:10.1177/875512250802400215 · Cited by 487
Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlén, S.-E., Holgate, S. T., Meyers, D. A., Rabe, K. F., Antczak, A., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200809-1512oc · Cited by 460
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., & Germinaro, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.032 · Cited by 426
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Changes in Sputum Eosinophils Predict Loss of Asthma Control
JATAKANON, A., LIM, S., & BARNES, P. J. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.1.9809100 · Cited by 404
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
Boulet, L. P., Chapman, K. R., Côté, J., Kalra, S., Bhagat, R., Swystun, V. A., Laviolette, M., Cleland, L. D., Deschesnes, F., Su, J. Q., et al. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196083 · Cited by 399
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Corren, J., Weinstein, S., Janka, L., Zangrilli, J., & Garin, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.018 · Cited by 388
Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206719 · Cited by 381
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00223411 · Cited by 373
Bilgiç Temel, A., Bassorgun, C. I., Akman-Karakaş, A., Alpsoy, E., & Uzun, S. (2017) · Case Reports in Dermatology · doi:10.1159/000452828 · Cited by 363
Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360
Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma
Brusselle, G. G., Maes, T., & Bracke, K. R. (2013) · Nature Medicine · doi:10.1038/nm.3300 · Cited by 316
Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing
Simoes, E. A. F., Groothuis, J. R., Carbonell-Estrany, X., Rieger, C. H. L., Mitchell, I., Fredrick, L. M., & Kimpen, J. L. L. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.02.032 · Cited by 305
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Corren, J., Busse, W., Meltzer, E. O., Mansfield, L., Bensch, G., Fahrenholz, J., Wenzel, S. E., Chon, Y., Dunn, M., Weng, H. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1448oc · Cited by 299
Wark, P. A. B., Hensley, M. J., Saltos, N., Boyle, M. J., Toneguzzi, R. C., Epid, G. D. C., Simpson, J. L., McElduff, P., & Gibson, P. G. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1388 · Cited by 298
Lugogo, N., Domingo, C., Chanez, P., Leigh, R., Gilson, M. J., Price, R. G., Yancey, S. W., & Ortega, H. G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.010 · Cited by 283
Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00533.x · Cited by 279
Busse, W. W., Katial, R., Gossage, D., Sari, S., Wang, B., Kolbeck, R., Coyle, A. J., Koike, M., Spitalny, G. L., Kiener, P. A., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.005 · Cited by 278
Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma
Bousquet, J., Wenzel, S., Holgate, S., Lumry, W., Freeman, P., & Fox, H. (2004) · Chest · doi:10.1378/chest.125.4.1378 · Cited by 277
Menzies-Gow, A., Flood-Page, P., Sehmi, R., Burman, J., Hamid, Q., Robinson, D. S., Kay, A. B., & Denburg, J. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1382 · Cited by 276
Mukherjee, M., Stoddart, A., Gupta, R. P., Nwaru, B. I., Farr, A., Heaven, M., Fitzsimmons, D., Bandyopadhyay, A., Aftab, C., Simpson, C. R., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0657-8 · Cited by 273
Targeting the interleukin pathway in the treatment of asthma
Chung, K. F. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00157-9 · Cited by 261
Massanari, M., Nelson, H., Casale, T., Busse, W., Kianifard, F., Geba, G. P., & Zeldin, R. K. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.022 · Cited by 230
Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma
Gauvreau, G. M., Boulet, L.-P., Cockcroft, D. W., FitzGerald, J. M., Carlsten, C., Davis, B. E., Deschesnes, F., Duong, M., Durn, B. L., Howie, K. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201008-1210oc · Cited by 230
Chervinsky, P., Casale, T., Townley, R., Tripathy, I., Hedgecock, S., Fowler-Taylor, A., Shen, H., & Fox, H. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62171-0 · Cited by 215
Ohman, J. L., Findlay, S. R., & Leitermann, K. M. (1984) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(84)90251-3 · Cited by 210
Relationship between IL-4 and IL-5 mRNA Expression and Disease Severity in Atopic Asthma
HUMBERT, M., CORRIGAN, C. J., KIMMITT, P., TILL, S. J., BARRY KAY, A., & DURHAM, S. R. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.3.9610033 · Cited by 209
Garcia, G., Magnan, A., Chiron, R., Contin-Bordes, C., Berger, P., Taillé, C., Devouassoux, G., de Blay, F., Couderc, L.-J., Didier, A., et al. (2013) · Chest · doi:10.1378/chest.12-1961 · Cited by 206
Nowak, R. M., Parker, J. M., Silverman, R. A., Rowe, B. H., Smithline, H., Khan, F., Fiening, J. P., Kim, K., & Molfino, N. A. (2015) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2014.09.036 · Cited by 206
Corren, J., Casale, T., Deniz, Y., & Ashby, M. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.49 · Cited by 188
Repeatability of Spirometry in 18,000 Adult Patients
Enright, P. L., Beck, K. C., & Sherrill, D. L. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-347oc · Cited by 186
Haldar, P., Brightling, C. E., Singapuri, A., Hargadon, B., Gupta, S., Monteiro, W., Bradding, P., Green, R. H., Wardlaw, A. J., Ortega, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.026 · Cited by 185
Reductions in eosinophil biomarkers by benralizumab in patients with asthma
Pham, T.-H., Damera, G., Newbold, P., & Ranade, K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.01.003 · Cited by 185
Omalizumab is effective in the long-term control of severe allergic asthma
Lanier, B. Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A., & Gupta, N. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62170-9 · Cited by 183
Berger, W., Gupta, N., McAlary, M., & Fowler-Taylor, A. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62175-8 · Cited by 182
Kopp, M. V., Hamelmann, E., Zielen, S., Kamin, W., Bergmann, K. ‐., Sieder, C., Stenglein, S., Seyfried, S., Wahn, U., & for the DUAL study group (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03121.x · Cited by 181
Clavel, R., Bousquet, J., & André, C. (1998) · Allergy · doi:10.1111/j.1398-9995.1998.tb04086.x · Cited by 179
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., Champain, K., Fox, H., Thirlwell, J., & Della Cioppa, G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00278102 · Cited by 179
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma
Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., & Gupta, N. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.54 · Cited by 173
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
Noonan, M., Korenblat, P., Mosesova, S., Scheerens, H., Arron, J. R., Zheng, Y., Putnam, W. S., Parsey, M. V., Bohen, S. P., & Matthews, J. G. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.051 · Cited by 171
Chandra, R. K., Singh, G., & Shridhara, B. (1989) · PubMed · Cited by 169
Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab
Noga, O., Hanf, G., & Kunkel, G. (2003) · International Archives of Allergy and Immunology · doi:10.1159/000070434 · Cited by 168
Assessing Future Need for Acute Care in Adult Asthmatics
Osborne, M. L., Pedula, K. L., O'Hollaren, M., Ettinger, K. M., Stibolt, T., Buist, A. S., & Vollmer, W. M. (2007) · Chest · doi:10.1378/chest.05-3084 · Cited by 168
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
Bousquet, J., Siergiejko, Z., Świebocka, E., Humbert, M., Rabe, K. F., Smith, N., Leo, J., Peckitt, C., Maykut, R., & Peachey, G. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02522.x · Cited by 168
Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting
Zeiger, R. S., Schatz, M., Dalal, A. A., Qian, L., Chen, W., Ngor, E. W., Suruki, R. Y., & Kawatkar, A. A. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2015.08.003 · Cited by 165
Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma
Hoshino, M., & Ohtawa, J. (2012) · Respiration · doi:10.1159/000334701 · Cited by 164
Thymic stromal lymphopoietin, OX40‐ligand, and interleukin‐25 in allergic responses
Wang, Y., & Liu, Y. J. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03241.x · Cited by 163
Lopez, A. F., Begley, C. G., Williamson, D. J., Warren, D. J., Vadas, M. A., & Sanderson, C. J. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.5.1085 · Cited by 162
Buhl, R., Hanf, G., Solèr, M., Bensch, G., Wolfe, J., Everhard, F., Champain, K., Fox, H., & Thirlwell, J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00016502 · Cited by 160
Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma
Busse, W. W., Israel, E., Nelson, H. S., Baker, J., Charous, B. L., Young, D. Y., Vexler, V. S., & Shames, R. S. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1200oc · Cited by 158
Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects
FAHY, J. V., COCKCROFT, D. W., BOULET, L.-P., WONG, H. H., DESCHESNES, F., DAVIS, E. E., RUPPEL, J., SU, J. Q., & ADELMAN, D. C. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9810012 · Cited by 158
Sugaya, N. (1994) · JAMA · doi:10.1001/jama.1994.03520140052037 · Cited by 148
Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial
Boever, E. H. D., Ashman, C., Cahn, A. P., Locantore, N., Overend, P., Pouliquen, I. J., Serone, A., Wright, T. J., Jenkins, M., Panesar, I. S., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.002 · Cited by 145
Oba, Y., & Salzman, G. A. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.05.049 · Cited by 142
Oh, C. K., Leigh, R., McLaurin, K. K., Kim, K., Hultquist, M., & Molfino, N. A. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-93 · Cited by 141
Slavin, R. G., Ferioli, C., Tannenbaum, S. J., Martin, C., Blogg, M., & Lowe, P. J. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.050 · Cited by 136
Bryant, D. H., Burns, M. W., & Lazarus, L. H. (1975) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1975.tb01847.x · Cited by 134
Gauvreau, G. M., Harris, J. M., Boulet, L., Scheerens, H., FitzGerald, J. M., Putnam, W. S., Cockcroft, D. W., Davis, B. E., Leigh, R., Zheng, Y., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008961 · Cited by 133
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
Scheerens, H., Arron, J. R., Zheng, Y., Putnam, W. S., Erickson, R. W., Choy, D. F., Harris, J. M., Lee, J., Jarjour, N. N., & Matthews, J. G. (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12220 · Cited by 128
EAACI position statement on asthma exacerbations and severe asthma
Custovic, A., Johnston, S. L., Pavord, I., Gaga, M., Fabbri, L., Bel, E. H., Le Souëf, P., Lötvall, J., Demoly, P., Akdis, C. A., et al. (2013) · Allergy · doi:10.1111/all.12275 · Cited by 127
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Brusselle, G., Germinaro, M., Weiss, S., & Zangrilli, J. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.01.011 · Cited by 127
Cabon, Y., Molinari, N., Marin, G., Vachier, I., Gamez, A. S., Chanez, P., & BOURDIN, A. A. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12853 · Cited by 122
Monoclonal anti-interleukin‐5 treatment suppresses eosinophil but not T‐cell functions
Büttner, C., Lun, A., Splettstoesser, T., Kunkel, G., & Renz, H. E. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027302 · Cited by 120
Caffarelli, C., SENSI, L. G., Marcucci, F., & Cavagni, G. (2000) · Allergy · doi:10.1034/j.1398-9995.2000.00655.x · Cited by 117
Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge
Eckman, J. A., Sterba, P. M., Kelly, D., Alexander, V., Liu, M. C., Bochner, B. S., MacGlashan, D. W., & Saini, S. S. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.012 · Cited by 117
Ortega, H. G., Li, H., Suruki, R., Albers, F. C., Gordon, D., & Yancey, S. W. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201312-454oc · Cited by 116
Álvarez-Cuesta, E., Cuesta‐Herranz, J., Puyana-Ruiz, J., Cuesta-Herranz, C., & Blanco-Quirós, A. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(94)70067-2 · Cited by 116
Soybean oil is not allergenic to soybean-sensitive individuals
Bush, R. K., Taylor, S., Nordlee, J. A., et al. (1985) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(85)90709-2 · Cited by 115
Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti‐IgE treatment
van Rensen, E. L. J., Evertse, C. E., van Schadewijk, W. A. A. M., van Wijngaarden, S., Ayre, G., Mauad, T., Hiemstra, P. S., Sterk, P. J., & Rabe, K. F. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01881.x · Cited by 114
OX 40L blockade and allergen‐induced airway responses in subjects with mild asthma
Gauvreau, G. M., Boulet, L. ‐., Cockcroft, D. W., FitzGerald, J. M., Mayers, I., Carlsten, C., Laviolette, M., Killian, K. J., Davis, B. E., Larché, M., et al. (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12235 · Cited by 114
Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study
van Veen, I. H., Brinke, A. T., Gauw, S. A., Sterk, P. J., Rabe, K. F., & Bel, E. H. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.029 · Cited by 114
Sehmi, R., Smith, S. G., Kjarsgaard, M., Radford, K., Boulet, L., Lemière, C., Prazma, C. M., Ortega, H. G., Martin, J. G., & Nair, P. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12695 · Cited by 113
Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma
Brown, R. E., Turk, F., Dale, P., & Bousquet, J. (2007) · Allergy · doi:10.1111/j.1398-9995.2006.01310.x · Cited by 110
Liu, Y., Zhang, S., Li, D., & Jiang, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059872 · Cited by 106
The early history of the eosinophil
Kay, A. B. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12480 · Cited by 105
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
Kulus, M., Hébert, J., García, E., Taylor, A. F., Vidaurre, C. F., & Blogg, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003771338 · Cited by 102
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Yancey, S. W., Ortega, H. G., Keene, O. N., Mayer, B., Gunsoy, N. B., Brightling, C. E., Bleecker, E. R., Haldar, P., & Pavord, I. D. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.008 · Cited by 101
Ong, Y. E., Menzies-Gow, A. N., Barkans, J. R., Benyahia, F., Ou, T.-T., Sun, Y., & Kay, A. B. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.035 · Cited by 97
Effect of omalizumab in health care workers with occupational latex allergy
Leynadier, F., Doudou, O., Gaouar, H., Gros, V., Bourdeix, I., Guyomarch-Cocco, L., & Trunet, P. F. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.11.020 · Cited by 93
Park, C., Choi, Y., Ki, S., Moon, S., Jeong, S., Uh, S.-T., & Kim, Y. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12040872 · Cited by 93
Silkoff, P. E., Romero, F. A., Gupta, N., Townley, R. G., & Milgrom, H. (2004) · PEDIATRICS · doi:10.1542/peds.113.4.e308 · Cited by 91
Efficacy and safety of omalizumab in an Asian population with moderate‐to‐severe persistent asthma
Ohta, K., Miyamoto, T., Amagasaki, T., Yamamoto, M., & on behalf of the 1304 Study Group (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01633.x · Cited by 90
Pouliquen, I. J., Kornmann, O., Barton, S. V., Price, J. A., & Ortega, H. G. (2015) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202446 · Cited by 86
Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients
Siergiejko, Z., Świebocka, E., Smith, N., Peckitt, C., Leo, J., Peachey, G., & Maykut, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.620950 · Cited by 84
Singh, D., Kane, B., Molfino, N. A., Faggioni, R., Roskos, L. K., & Woodcock, A. A. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-3 · Cited by 84
Niven, R. M., Chung, K. F., Panahloo, Z., Blogg, M., & Ayre, G. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.06.002 · Cited by 84
Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy
Kopp, M., Hamelmann, E. H., Bendiks, M., Zielen, S., Kamin, W., Bergmann, K., Klein, C., Wahn, U., & The DUAL study group (2013) · Pediatric Allergy and Immunology · doi:10.1111/pai.12098 · Cited by 79
Sorkness, C. A., Wildfire, J. J., Calatroni, A., Mitchell, H., Busse, W. W., O’Connor, G. T., Pongracic, J. A., Ross, K. R., Gill, M. A., Kattan, M., et al. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.01.011 · Cited by 79
Mepolizumab versus placebo for asthma
Powell, C., Milan, S. J., Dwan, K. M., Bax, L., & Walters, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010834.pub2 · Cited by 75
Self-citationIdentification of IgG antibody as a carrier of reaginic activity in asthmatic patients
Bryant, D. H., Burns, M. W., & Lazarus, L. H. (1975) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(75)90060-3 · Cited by 73
Wang, F., Liu, T., Zhu, L., Li, S., & Mao, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166833 · Cited by 68
Kon, O. M., Sihra, B. S., Loh, L., Barkans, J. R., Compton, C. H., Barnes, N., Larché, M., & Kay, A. B. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00064101 · Cited by 67
The Role of Immunotherapy in Cockroach Asthma
Rang, B. C., Johnson, J., Morgan, C., & Chang, J. L. (1988) · Journal of Asthma · doi:10.3109/02770908809071367 · Cited by 64
Hodsman, P., Ashman, C., Cahn, A. P., Boever, E. H. D., Locantore, N., Serone, A., & Pouliquen, I. J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04334.x · Cited by 61
Pauli, G., Bessot, J. C., Bigot, H., Delaume, G., Hordle, D. A., Hirth, C., & Thierry, R. (1984) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(84)90389-0 · Cited by 57
Humbert, M. J. C., Boulet, L. P., Niven, R. M., Panahloo, Z., Blogg, M., & Ayre, G. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01846.x · Cited by 55
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Pelaia, G., Vatrella, A., Busceti, M. T., Gallelli, L., Preianò, M., Lombardo, N., Terracciano, R., & Maselli, R. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s111862 · Cited by 53
Basophil Histamine Release Decreases during Omalizumab Therapy in Allergic Asthmatics
Noga, O., Hanf, G., Kunkel, G., & Kleine‐Tebbe, J. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000112504 · Cited by 45
Effect of Omalizumab on Adenosine 5′-Monophosphate Responsiveness in Subjects with Allergic Asthma
Prieto, L. M., Gutiérrez, V., Colás, C., Tabar, A. I., Pérez‐Francés, C., Bruno, L., & Uixera, S. (2005) · International Archives of Allergy and Immunology · doi:10.1159/000090387 · Cited by 43
Zielen, S., Lieb, A., Motte, S. D. L., Wagner, F. D., de Monchy, J., Fuhr, R., Munzu, C., Koehne‐Voss, S., Rivière, G., Kaiser, G., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000339243 · Cited by 43
Humbert, M. J. C., Berger, W. L., Rapatz, G., & Turk, F. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01654.x · Cited by 41
Moss, R. B., Hsu, Y., Kwasnicki, J. M., Sullivan, M. M., & Reid, M. J. A. (1987) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(87)90160-6 · Cited by 39
Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Shimoda, T., Odajima, H., Okamasa, A., Kawase, M., Komatsubara, M., Mayer, B., Yancey, S. W., & Ortega, H. G. (2017) · Allergology International · doi:10.1016/j.alit.2016.11.006 · Cited by 39
Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma
Ayars, A. G., Altman, L. C., Potter‐Perigo, S., Radford, K., Wight, T. N., & Nair, P. K. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000343031 · Cited by 38
ZETTERSTRÖM, O., FAGERBERG, E., & WIDE, L. E. (1972) · Allergy · doi:10.1111/j.1398-9995.1972.tb01638.x · Cited by 37
Li, J., Wang, F., Lin, C., Du, J., Xiao, B., Du, C., & Sun, J. (2016) · Journal of Asthma · doi:10.1080/02770903.2016.1212371 · Cited by 36
Effects of anti-IgE in asthmatic subjects
Frew, A. J. (1998) · Thorax · doi:10.1136/thx.53.2008.s52 · Cited by 35
Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy
Hendeles, L., Khan, Y. R., Shuster, J. J., Chesrown, S. E., & Abu‐Hasan, M. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.10.012 · Cited by 29
Double‐blind, placebo‐controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters
Lizaso, M. T., Tabar, A. I., García, B. E., Gómez, B., Algorta, J., Asturias, J. A., & Martı́nez, A. (2007) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2007.00587.x · Cited by 24
The best laid schemes of airway repair
Rawlins, E. L., & Giangreco, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00088014 · Cited by 22
Hanania, N. A., Noonan, M. J., Corren, J., Korenblat, P. E., Zheng, Y., Putnam, W. S., Murray, E., Abelardo, C., Scheerens, H., Maciuca, R. D., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.1064 · Cited by 21
Weinstein, S. F., Germinaro, M., Bardin, P. G., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.409 · Cited by 20
Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics
Rose, M. A., Gruendler, M., Schubert, R., Kitz, R., Schulze, J., & Zielen, S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.054 · Cited by 19
Basu, A., Dalal, A. A., Canonica, G. W., Forshag, M. S., Yancey, S. W., Nagar, S. P., & Bell, C. F. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1298444 · Cited by 18
Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Massanari, M. J., Kianifard, F., Zeldin, R. K., & Geba, G. P. (2009) · Allergy and Asthma Proceedings · doi:10.2500/aap.2009.30.3245 · Cited by 13
Zhu, R., Zheng, Y., Putnam, W. S., Visich, J. E., Eisner, M. D., Matthews, J. G., Rosén, K. E., & D’Argenio, D. Z. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9463-9 · Cited by 12
Greenberg, R. N., Km, W., Ay, K., Wedel, N. I., & Kj, G. (1991) · PubMed · Cited by 12
Busse, W. W., Wang, M., Gibson, J., Gottlow, M., Braddock, M., & Colice, G. (2015) · Clinical Investigation · doi:10.4155/cli.15.37 · Cited by 11
Gordon, V. H., Kj, C., Jh, M., & Thompson, C. (1972) · PubMed · Cited by 11
Bel, E. H., Wenzel, S., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S., Ortega, H., & Pavord, I. D. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.2907 · Cited by 10
Castro, M., Zangrilli, J., & Wechsler, M. E. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00119-8 · Cited by 4
Lebrikizumab reduces serum periostin in asthma patients with elevated baseline periostin
Scheerens, H., Arron, J. R., Choy, D. F., et al. (2012) · European Respiratory Journal · Cited by 3
Cited by
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
McGregor, M. C., Krings, J. G., Nair, P., & Castro, M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1944ci · Cited by 432
EUFOREA consensus on biologics for CRSwNP with or without asthma
Fokkens, W. J., Lund, V., Bachert, C., Mullol, J., Bjermer, L., Bousquet, J., Canonica, G. W., Deneyer, L., Desrosiers, M., Diamant, Z., et al. (2019) · Allergy · doi:10.1111/all.13875 · Cited by 390
Opposing roles of eosinophils in cancer
Simon, S. C. S., Utikal, J., & Umansky, V. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2255-4 · Cited by 128
Innate Lymphoid Cells Play a Pathogenic Role in Pericarditis
Choi, H. S., Won, T., Hou, X., Chen, G., Bracamonte-Baran, W., Talor, M. V., Jurčová, I., Szárszoi, O., Čurnova, L., Stříž, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.040 · Cited by 43
Metadata
- Authors
- Farne, H. A., Wilson, A., Powell, C., Bax, L., & Milan, S. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-09-21
- Volume
- 9
- Pages
- CD010834-CD010834
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2757963532
- Cited by
- 315
- References
- 167
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.